Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
10:55am, Friday, 09'th Aug 2024
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
08:00am, Tuesday, 06'th Aug 2024
NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial res
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
08:50am, Tuesday, 30'th Jul 2024
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Off
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet
10:13am, Sunday, 30'th Jun 2024
Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, t
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
01:03pm, Monday, 03'rd Jun 2024
Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectivel
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Rela
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
08:00am, Thursday, 30'th May 2024
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Offi
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
05:05pm, Thursday, 23'rd May 2024
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster pres
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
08:00am, Thursday, 09'th May 2024
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Offi
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
08:00am, Tuesday, 07'th May 2024
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, to
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
08:00am, Wednesday, 01'st May 2024
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Offi
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
04:05pm, Wednesday, 24'th Apr 2024
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data fro
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
02:30pm, Friday, 19'th Apr 2024
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
08:00am, Tuesday, 02'nd Apr 2024
NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio,
Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
09:10am, Sunday, 17'th Mar 2024
The Oracle of Omaha has once more bolstered his stake in a media giant's tracking stocks.
